Last10K.com

21St Century Oncology Holdings, Inc. (RTSX) SEC Filing 10-Q Quarterly report for the period ending Wednesday, September 30, 2015

21St Century Oncology Holdings, Inc.

CIK: 1503518 Ticker: RTSX

Exhibit 99.1

 

 21ST CENTURY ONCOLOGY HOLDINGS, INC.

 CONDENSED CONSOLIDATED BALANCE SHEETS

 (in thousands, except share amounts)

 (unaudited)

 

 

 

PRELIMINARY

 

ADJUSTMENTS

 

 

 

FINAL

 

 

 

 

September 30,

 

September 30,

 

 

 

September 30,

 

 

 

 

2015

 

2015

 

 

 

2015

 

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

Current assets:

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

47,793

 

$

 

 

 

$

47,793

 

 

Restricted cash

 

80

 

 

 

 

80

 

 

Marketable securities

 

622

 

 

 

 

622

 

 

Accounts receivable, net

 

149,224

 

 

 

 

149,224

 

 

Prepaid expenses

 

9,381

 

 

 

 

9,381

 

 

Inventories

 

5,162

 

 

 

 

5,162

 

 

Deferred income taxes

 

191

 

 

 

 

191

 

 

Other

 

8,056

 

 

 

 

8,056

 

 

Total current assets

 

220,509

 

 

 

 

220,509

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity investments in joint ventures

 

1,236

 

 

 

 

1,236

 

 

Property and equipment, net

 

249,392

 

 

 

 

249,392

 

 

Real estate subject to finance obligation

 

11,625

 

 

 

 

11,625

 

 

Goodwill

 

492,084

 

 

 

 

492,084

 

 

Intangible assets, net

 

74,434

 

 

 

 

74,434

 

 

Other assets

 

49,282

 

 

 

 

49,282

 

 

Total assets

 

$

1,098,562

 

$

 

 

 

$

1,098,562

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

59,397

 

$

 

 

 

$

59,397

 

 

Accrued expenses

 

111,084

 

28,977

 

A

 

140,061

 

 

Income taxes payable

 

1,814

 

 

 

 

1,814

 

 

Current portion of long-term debt

 

30,858

 

 

 

 

30,858

 

 

Current portion of finance obligation

 

481

 

 

 

 

481

 

 

Other current liabilities

 

6,484

 

 

 

 

6,484

 

 

Total current liabilities

 

210,118

 

28,977

 

 

 

239,095

 

 

Long-term debt, less current portion

 

1,009,196

 

 

 

 

1,009,196

 

 

Finance obligation, less current portion

 

12,057

 

 

 

 

12,057

 

 

Embedded derivative & other financial instrument features of Series A convertible redeemable preferred stock

 

23,541

 

3,798

 

B

 

27,339

 

 

Other long-term liabilities

 

39,861

 

 

 

 

39,861

 

 

Deferred income taxes

 

3,716

 

 

 

 

3,716

 

 

Total liabilities

 

1,298,489

 

32,775

 

 

 

1,331,264

 

 

 

 

 

 

 

 

 

 

 

 

 

Series A convertible redeemable preferred stock, $0.001 par value, $1,000 stated value, 3,500,000 authorized, 385,000 issued and outstanding at September 30, 2015 and December 31, 2014

 

404,179

 

(33,701

)

C

 

370,478

 

 

Noncontrolling interests - redeemable

 

19,934

 

 

 

 

19,934

 

 

 

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity:

 

 

 

 

 

 

 

 

 

 

Common stock, $0.01 par value, 1,000,000 shares authorized 1,059 and 1,028 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively

 

 

 

 

 

 

 

Additional paid-in capital

 

569,036

 

30,697

 

D

 

599,733

 

 

Retained deficit

 

(1,174,400

)

(29,771

)

E

 

(1,204,171

)

 

Accumulated other comprehensive loss, net of tax

 

(45,008

)

 

 

 

(45,008

)

 

Total 21st Century Oncology Holdings, Inc. shareholder’s deficit

 

(650,372

)

926

 

 

 

(649,446

)

 

Noncontrolling interests - nonredeemable

 

26,332

 

 

 

 

26,332

 

 

Total deficit

 

(624,040

)

926

 

 

 

(623,114

)

 

Total liabilities and equity

 

$

1,098,562

 

$

 

 

 

$

1,098,562

 

 


The following information was filed by 21St Century Oncology Holdings, Inc. (RTSX) on Friday, February 12, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate 21St Century Oncology Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by 21St Century Oncology Holdings, Inc..

Continue

Assess how 21St Century Oncology Holdings, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

21St Century Oncology Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Cash Flows (parenthetical)
Condensed Consolidated Statements Of Operations And Comprehensive Loss
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Acquisitions And Other Arrangements
Acquisitions And Other Arrangements (narrative) (details)
Acquisitions And Other Arrangements (schedule Of Estimated Future Amortization Expense) (details)
Acquisitions And Other Arrangements (schedule Of Preliminary Intangible Assets Included In Net Identifiable Assets) (details)
Acquisitions And Other Arrangements (schedule Of The Allocation Of The Purchase Price) (details)
Acquisitions And Other Arrangements (schedule Of Unaudited Pro Forma Financial Information) (details)
Acquisitions And Other Arrangements (summary Of Allocation Of The Aggregate Purchase Price, Including Assumed Liabilities) (details)
Acquisitions And Other Arrangements (tables)
Basis Of Presentation
Basis Of Presentation (details)
Basis Of Presentation (policy)
Commitments And Contingencies
Commitments And Contingencies (details)
Comprehensive Loss
Comprehensive Loss (narrative) (details)
Comprehensive Loss (schedule Of Components Of Accumulated Other Comprehensive Loss) (details)
Comprehensive Loss (tables)
Derivative Agreements
Derivative Agreements (narrative) (details)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (narrative) (details)
Fair Value Of Financial Instruments (schedule Of Changes In Level 3 Liabilities) (details)
Fair Value Of Financial Instruments (schedule Of Fair Value Debt Instruments Based On Level 2) (details)
Fair Value Of Financial Instruments (schedule Of Items Measured At Fair Value On Recurring Basis) (details)
Fair Value Of Financial Instruments (tables)
Goodwill
Goodwill (schedule Of Changes In The Carrying Amount Of Goodwill) (details)
Goodwill (schedule Of Impairment Loss) (details)
Goodwill (tables)
Income Taxes
Income Taxes (details)
Leverage And Liquidity
Leverage And Liquidity (details)
Long-term Debt
Long-term Debt (narrative) (details)
Long-term Debt (schedule Of Company's Long-term Debt) (details)
Long-term Debt (schedule Of Financial Covenants Compliance Under The Revolving Credit Facility) (details)
Long-term Debt (tables)
Organization
Organization (details)
Reconciliation Of Total Equity
Reconciliation Of Total Equity (details)
Reconciliation Of Total Equity (tables)
Redeemable Preferred Stock
Redeemable Preferred Stock (narrative) (details)
Redeemable Preferred Stock (schedule Of Changes To Series A Preferred Stock) (details)
Redeemable Preferred Stock (tables)
Segment And Geographic Information
Segment And Geographic Information (narrative) (details)
Segment And Geographic Information (schedule Of Financial Information By Geographic Segment) (details)
Segment And Geographic Information (schedule Of Reconciliation Of The Company's Reportable Segment Profit And Loss) (details)
Segment And Geographic Information (tables)
Stock-based Compensation
Stock-based Compensation (narrative) (details)
Stock-based Compensation (summary Of Units Activity Under The Plan) (details)
Stock-based Compensation (tables)
Subsequent Events
Subsequent Events (details)
Ticker: RTSX
CIK: 1503518
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-16-096509
Submitted to the SEC: Fri Feb 12 2016 2:31:52 PM EST
Accepted by the SEC: Fri Feb 12 2016
Period: Wednesday, September 30, 2015
Industry: Offices And Clinics Of Doctors Of Medicine

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rtsx/0001104659-16-096509.htm